Phosphate-additive reduction (dietary)

Phosphate-additive reduction is a dietary modification strategy targeting the avoidance of inorganic phosphate food additives — sodium phosphate, sodium tripolyphosphate, sodium acid pyrophosphate, dipotassium phosphate, and phosphoric acid — which are used in processed foods as emulsifiers, moisture-retention agents, leavening agents, and acidulants. The core rationale is a bioavailability differential: inorganic phosphate additives are absorbed rapidly and more completely because they exist as free ionic species requiring no enzymatic hydrolysis, while naturally occurring phosphate in whole foods (bound in phytate, phospholipids, and phosphoproteins) is absorbed at lower efficiency after enzymatic cleavage ¹². The specific absorption ranges cited in the review literature (~80–100% for inorganic additives vs ~40–60% for organic-matrix-bound phosphate) are synthesis-level estimates; Calvo 2023 characterizes the differential qualitatively as “rapidly and more completely absorbed” without providing these specific percentages directly. dose-response-unclear — precise absorption fractions are review-level estimates from metabolic studies; the exact differential is not pinned by a single controlled comparison study. The same milligrams on a nutrition label therefore correspond to dramatically different absorbed phosphate doses depending on food source — making additive intake, not total phosphorus intake, the biologically relevant target.

This page is one of a 3-page cluster covering the Klotho–FGF23–phosphate axis: fgf23 (protein, sibling-seeded), vascular-calcification (process, sibling-seeded), and this intervention page. Depth on the molecular mechanism lives on the sibling pages; this page anchors the dietary-modification frame.

Why the bioavailability differential matters

The distinction between inorganic and organic phosphate is the central mechanistic justification for targeting additives specifically rather than restricting dietary phosphorus generally.

Organic-matrix phosphate (whole foods):

Bound as phytate (inositol hexaphosphate) in grains, legumes, and nuts — requires intestinal phytase activity for release; fractional absorption typically 20–50% in human metabolic studies
Bound in phospholipids (phosphatidylcholine, phosphatidylethanolamine) in cell membranes of meat, eggs, and dairy — requires phospholipase activity; absorbed at ~40–60%
Bound in casein phosphopeptides in dairy — partial phytase/protease liberation required; intermediate absorption (~50–70%)
Net: organic-matrix phosphate absorption is enzyme-dependent and inherently partial

Inorganic additive phosphate (processed foods):

Added as free ionic salts (HPO₄²⁻, H₂PO₄⁻, P₂O₇⁴⁻) — immediately bioavailable in the gut lumen without enzymatic hydrolysis
Net: absorbed at ~80–100% across the intestinal brush border via sodium-phosphate cotransporters (NaPi-2b / SLC34A2)

Population-level consequence: Inorganic additives contribute an estimated 320–470 mg/day phosphorus to modern processed-food diets — roughly 20–30% of total phosphorus by mass but a disproportionately higher share of absorbed phosphorus ¹². Additive phosphate intake is estimated to have risen 17–30% over the past 20–30 years as processed-food market share expanded.

Phosphate source	Approximate absorption	Key limiting step
Phytate-bound (grains, legumes, seeds)	~20–50%	Intestinal phytase; incomplete in humans (low endogenous phytase)
Phospholipid-bound (cell membranes)	~40–60%	Phospholipase A₁/A₂
Casein phosphopeptides (dairy)	~50–70%	Protease + phosphatase activity
Inorganic phosphate salts (food additives)	~80–100%	None — free ionic species

dose-response-unclear — the exact absorption fraction varies between studies and is subject to transit time, gut microbiome composition, and background phosphorus status; the 40–60% vs 80–100% range is an approximate consensus from review-level sources rather than a tightly pinned RCT estimate ¹.

Additive sources — hierarchy of exposure

The following table reflects typical additive phosphate content per serving, derived from food-label analysis and additive-use review literature ²¹. These figures are approximate; individual branded products vary. Always read ingredient labels: any entry containing “phosphate,” “phosphoric acid,” or “pyrophosphate” indicates an inorganic additive source.

Source class	Additive phosphate per serving (approximate)	Additive type	Key labels to look for
Processed cheese (Kraft Singles, Velveeta, American “cheese products”)	~150–250 mg per slice/serving	Sodium phosphate, sodium aluminum phosphate, disodium phosphate	”Sodium phosphate” near top of ingredients
Processed meats (bacon, ham, hot dogs, deli turkey/chicken)	~200–400 mg per 2–3 oz serving	Sodium tripolyphosphate (moisture retention), sodium phosphate	”Tripolyphosphate” in ingredients
Frozen meals / prepared entrées	~200–500 mg per meal	Multiple phosphate types for moisture + texture stability	Any “phosphate” in a multi-ingredient ingredient list
Plant-based meat alternatives	~100–300 mg per serving	Disodium phosphate, dipotassium phosphate (binding)	“Dipotassium phosphate,” “disodium phosphate”
Cola beverages (Coca-Cola, Pepsi, generic cola)	~40–70 mg per 12 fl oz	Phosphoric acid (acidulant)	“Phosphoric acid” in ingredients
Non-dairy creamers, powdered beverage mixes	~50–150 mg per serving	Dipotassium phosphate (emulsifier)	“Dipotassium phosphate” near top
Commercial baked goods (cake mixes, biscuits, pancake mixes, fast-food biscuits)	~50–100 mg per serving	Sodium acid pyrophosphate (SAPP, chemical leavening)	“Sodium acid pyrophosphate” or “SAPP”
Some packaged breakfast cereals	~50–150 mg per serving	Tricalcium phosphate (fortification) + processing additives	”Tricalcium phosphate,” “calcium phosphate”

Cumulative daily exposure in a typical processed-food day: A day that includes a Kraft Single + a 12 oz cola + a serving of processed deli turkey + a frozen dinner delivers roughly 600–1,200 mg of additive phosphate alone. This is the load range at which hormonal disruption (PTH elevation, FGF23 signalling changes) has been reported in dietary intervention studies ¹. needs-replication — the specific threshold at which FGF23 elevation becomes measurable in healthy non-CKD adults from additive exposure alone is not established; Ritz 2012 is a review focused on CKD patients, not a controlled study of this threshold in the general population.

Additive-free whole-food phosphorus sources (high content but low-bioavailability): chicken breast, eggs, Greek yogurt, tuna, legumes, whole grains, nuts, seeds. These raise serum phosphate less per milligram consumed than additive sources, and do not trigger the same acute FGF23 response seen with equivalent inorganic doses ³⁴.

Mechanism — the Klotho/FGF23/phosphate axis

This section provides a summary of the mechanism. Full molecular detail lives on the sibling pages.

Step 1: Acute FGF23 elevation after inorganic phosphate ingestion

High-phosphate dietary exposures over several days can induce modest increases in FGF23 ¹. The acute FGF23 response to a single inorganic phosphate load appears modest in short-duration studies — an 8-hour post-prandial study in healthy young men (Volk et al. 2022) found significant PTH increase but NOT a significant FGF23 increase — suggesting FGF23 elevation may require sustained rather than acute phosphate loading ¹. FGF23 is a bone-derived phosphatonin hormone secreted by osteoblasts/osteocytes in direct response to extracellular phosphate; its physiological role is to promote renal phosphate excretion (reducing NaPi-2a/NaPi-2c cotransporters in the proximal tubule) and suppress 1,25-(OH)₂ vitamin D synthesis. Inorganic phosphate additives, absorbed with near-complete efficiency, spike portal and then systemic phosphate more rapidly and at higher magnitude than equivalent doses of organic-matrix phosphate. needs-replication — the claim that a single additive-heavy meal acutely and reliably elevates serum FGF23 within hours in healthy non-CKD adults is not robustly established; controlled studies show modest or non-significant acute FGF23 responses; the hormonal dysregulation appears to require chronic sustained exposure. See fgf23 for full protein-level detail.

Step 2: Chronic sustained FGF23 → Klotho downregulation

Sustained chronic phosphate-additive intake maintains chronically elevated circulating FGF23. FGF23 signals through FGFR1/3/4 receptors using membrane Klotho as an obligate co-receptor. Chronic high FGF23 leads to receptor-level downregulation of Klotho expression — both the membrane-bound (αKlotho) form and the soluble form shed into circulation. This Klotho decline removes a key anti-aging endocrine signal: αKlotho is a co-receptor for multiple FGF ligands and also has phosphaturic, anti-oxidant, and anti-senescent cell-signalling functions independent of FGF23. See klotho for full detail. needs-replication — the direct causal link from habitual dietary inorganic phosphate intake → sustained iFGF23 elevation → Klotho downregulation has been inferred from cross-sectional associations and postprandial intervention studies; a controlled long-duration dietary study in healthy non-CKD adults with both FGF23 and Klotho measured is lacking.

Step 3: Vascular smooth muscle cell transdifferentiation

Elevated extracellular phosphate is the necessary driver of vascular smooth muscle cell (VSMC) osteogenic transdifferentiation — the process by which VSMCs convert from a contractile to an osteoblast-like phenotype, depositing calcium-phosphate mineral in the arterial wall and producing vascular-calcification. The Pit-1 (SLC20A1) sodium-phosphate cotransporter on VSMCs imports phosphate directly, activating downstream Runx2, BMP2, and osteocalcin expression. This is not simply a passive precipitation process — it requires active cellular uptake and gene expression changes. See vascular-calcification for full mechanistic detail. needs-human-replication — the in-vitro VSMC transdifferentiation evidence is strong; the corresponding in-vivo human evidence relies on cohort associations between dietary phosphate intake and coronary artery calcification (CAC) rather than controlled mechanistic studies.

Renal stress (minor contribution in healthy kidneys)

Increased phosphate absorption requires increased renal phosphate excretion, modestly increasing tubular phosphate reabsorption load. In healthy kidneys with full GFR, this is handled without clinical consequence and does not cause measurable renal injury. The mechanism becomes pathologically relevant at GFR <60 mL/min/1.73 m² (CKD stages 3+), where impaired phosphate excretion drives the CKD–mineral bone disorder (CKD-MBD) syndrome.

Evidence base — honest grading

This section explicitly distinguishes cohort evidence, mechanism evidence, and RCT evidence. The non-CKD hard-endpoint RCT evidence is absent.

Cohort evidence — strong

Dhingra et al. 2007 (Framingham Offspring, Arch Intern Med): Among 3,368 adults without established CVD at baseline, serum phosphorus in the upper quartile of the normal range (quartile cutoff values not reported in the abstract; unsourced — specific mg/dL thresholds require full-text verification against closed-access paper) was associated with approximately 1.55-fold higher risk of new cardiovascular disease events (HR 1.55, 95% CI 1.16–2.07, p=0.004) over ~16 years of follow-up in multivariable-adjusted analysis. Effect was graded and monotonic across the normal phosphorus range, not threshold-based. This is the foundational non-CKD cohort observation ⁵. Limitations: serum phosphate is a single measurement at baseline; dietary intake was not directly measured; residual confounding by diet quality is possible.

Foley (commentary, 2007) and Foley et al. ARIC 2008: Foley’s accompanying 2007 editorial in the same journal issue contextualized the Dhingra findings within the emerging phosphate-as-cardiovascular-risk-factor literature ⁶. The ARIC study (Foley et al. 2008, Am Heart J) confirmed across 15,732 community-dwelling adults that higher serum calcium-phosphate product was associated with increased risk of stroke (HR 1.15, 95% CI 1.05–1.26) and all-cause mortality (HR 1.15, 95% CI 1.09–1.20) — extending the Framingham finding in a more racially and geographically diverse cohort ⁷. Notably, the association with coronary heart disease was not significant (HR 1.03, 95% CI 0.98–1.08). The ARIC analysis emphasized the calcium-phosphate product (Ca × P) and serum phosphate separately, with broadly similar effect estimates for both. Limitations: observational; confounding by CKD even at “normal” GFR; dietary phosphate source data absent.

FGF23 as proximate biomarker — controlled dietary evidence (partial)

Gutiérrez OM et al. 2010 (postprandial study, Nephrol Dial Transplant): Using a postprandial mineral handling design in 28 healthy adults (10 Black, 18 white) and 19 CKD patients (10 Black, 9 white), demonstrated that postprandial FGF23 did NOT significantly change over the 4-hour observation period in either racial group or CKD status. Serum phosphate likewise did not significantly differ between groups over time. The key finding was that Black participants had ~30% lower fractional excretion of phosphate than white participants despite similar PTH and FGF23 concentrations, suggesting racial differences in renal sensitivity to phosphaturic hormones — not a FGF23 response pathway. unsourced — the claim that “FGF23 elevates within hours” after an inorganic phosphate meal cannot be attributed to this paper; it requires a different citation (e.g., Gutiérrez OM et al. 2015 J Clin Endocrinol Metab, or Volk et al. 2022) ⁴.

Karp et al. 2007 (Calcified Tissue International): A whole-foods controlled feeding study in young women examined acute calcium and bone metabolic responses to different phosphorus food sources, demonstrating source-specific differences in calcium and phosphate fluxes consistent with bioavailability differences across phosphate matrix forms ³. Limitations: short-term, young women, bone metabolism primary endpoint rather than FGF23 or cardiovascular surrogates.

Synthesis reviews — the canonical evidence summaries

Ritz et al. 2012 (Deutsches Ärzteblatt International): The major public-health consensus review arguing for mandatory phosphate additive labeling in the EU and other jurisdictions. Synthesizes the bioavailability differential, the additive-intake estimates (~20–30% of total dietary phosphorus), and the FGF23/vascular mechanism pathway. Argues the regulatory framework for food additive phosphates — which are labeled by aggregate category rather than specific quantities — renders individualized exposure assessment by consumers impossible ².

Calvo et al. 2023 (Nutrients): The most recent authoritative synthesis, explicitly framing industrial phosphate additives as “a mechanism linking ultra-processed food intake to cardiorenal disease risk.” Discusses additive use categories (emulsifiers in processed cheese, moisture-retention in meats, leavening in baked goods, acidulant in cola), updated bioavailability differential, FGF23 evidence, and regulatory gaps. Open-access (gold) ¹.

Calvo & Tucker 2013 (Ann NY Acad Sci): Canonical review on phosphorus intake exceeding dietary requirements as a health risk — covers bone, kidney, and cardiovascular dimensions. Reviews the additive-intake estimates (320–470 mg/day from additives in a typical U.S. processed-food diet) and the FGF23 evidence base as of 2013 ⁸.

CKD-population RCT evidence — stronger but extrapolation required

Multiple RCTs in CKD populations (stages 3–5 and dialysis) demonstrate that phosphate binder therapy + dietary phosphate restriction reduces FGF23 ⁹ and is associated with reduced CV mortality in systematic reviews. The mechanism chain — high phosphate → high FGF23 → vascular calcification → CV mortality — is strongest in the CKD context where phosphate dysregulation is severe. Extrapolation to non-CKD individuals is biologically plausible (same hormonal axis, lower magnitude) but not directly demonstrated by hard-endpoint RCTs.

Hard-endpoint RCT evidence in non-CKD adults — ABSENT

No multi-year RCT has randomized non-CKD adults to high vs. low inorganic-phosphate-additive dietary patterns and measured CV event rates or coronary artery calcification progression. The translation-gap: phase-3-rct-needed designation reflects this directly. The bioavailability differential and cohort associations are well-established; the gap is causal demonstration in the primary-prevention population.

Hallmarks targeted

Hallmark	Mechanism pathway	Evidence tier
chronic-inflammation	FGF23/Klotho dysregulation → VSMC inflammatory activation → arterial wall inflammation and calcification	Cohort + mechanism; no direct anti-inflammatory RCT in non-CKD
deregulated-nutrient-sensing	Phosphate is a nutrient sensed via the FGF23/Klotho/PTH/Vitamin D endocrine axis; additive load chronically dysregulates this axis	Mechanistic; FGF23 is the proximate biomarker of deregulation

Recency literature search results (R25 — 2026-05-23)

R25 search conducted: PubMed eutils, date filters 2020–2026-05-23; queries: phosphate additives AND cardiovascular (351 results), FGF23 AND dietary phosphate (120 results), phosphorus intake AND vascular calcification AND non-CKD (1 result), phosphate food additive FGF23 cardiovascular meta-analysis OR RCT OR systematic review (19 results, screened).

Triage outcome: No new RCTs or meta-analyses in non-CKD adults were identified in the 2022–2026 window that change the bottom line. The field has not produced a primary-prevention hard-endpoint trial. The Calvo et al. 2023 (doi:10.3390/nu15163510) review is the most recent high-quality synthesis identified.

Calvo 2023 key update vs. training-era knowledge: Explicitly frames phosphate additives as an ultra-processed food mechanism, integrating the NOVA food-classification system with the phosphate bioavailability argument. The framing has strengthened from a “phosphorus is high in modern diets” nutritional concern to a “ultra-processed foods deliver a qualitatively different phosphate exposure” mechanistic claim. This is consistent with training-era understanding, not contradictory.

ClinicalTrials.gov (2026-05-23): Active trials queried for “FGF23 dietary phosphate” and “phosphate additive reduction.” Three active trials found, all CKD-specific (NCT06377293, NCT07368946, NCT07312981). No active trials in non-CKD adults on dietary phosphate-additive reduction. clinical-trials-active: 0 for non-CKD primary-prevention indication.

Practical implementation

The intervention reduces to a pattern shift: whole-food sourcing of protein, dairy, and beverages eliminates the dominant additive-phosphate categories without requiring calorie restriction or protein restriction.

Swap table — actionable at the grocery level

Replace	With	Additive phosphate eliminated per swap	Other nutritional change
Kraft Single / processed cheese / Velveeta	Real cheddar, parmesan, Gruyère, provolone, Swiss	~150–250 mg/slice	No added emulsifiers; ~30–50% less sodium typically
Cola beverages (any brand with phosphoric acid)	Sparkling water, water, brewed coffee, unsweetened tea	~40–70 mg/12 oz	Also eliminates added sugar (in standard cola) or aspartame
Processed deli meats (most oven-roasted turkey, ham, bacon, hot dogs)	Home-roasted chicken or turkey, fresh-cut pork, fresh fish	~200–400 mg/2–3 oz serving	Also eliminates nitrites/nitrates and sodium significantly
Plant-based meat alternatives (most brands: Beyond, Impossible, etc.)	Whole plant proteins: lentils, tempeh, tofu, edamame, canned beans	~100–300 mg/serving	Adds fiber; lower processing index; lower sodium
Frozen TV dinner / prepared frozen entrée	Home-cooked meal from whole-ingredient components	~200–500 mg/meal	Highly variable; usually lower sodium as well
Non-dairy creamer / flavored powdered drink mix	Real milk/cream, unsweetened oat milk, brewed coffee/tea	~50–150 mg/serving	Eliminates refined oils and added sugars (non-dairy creamer)
Commercial biscuit/pancake mix, fast-food biscuits	Home baking with baking soda + cream of tartar instead of SAPP	~50–100 mg/serving	Structural baking change; no net nutritional deficit

The architectural principle: Individual swaps matter, but the cumulative daily pattern matters more. A day with Kraft Single + cola + processed deli turkey + frozen dinner can deliver 600–1,200 mg of additive phosphate. Eliminating those four categories reduces additive exposure to near-zero with no impact on protein intake, caloric intake, or dietary quality if the swaps above are used.

Ingredient-label reading skill: The intervention requires reading ingredient labels rather than relying on nutrition facts panels (which list total phosphorus, not inorganic additive phosphorus specifically). Any ingredient entry containing “phosphate” (sodium phosphate, disodium phosphate, dipotassium phosphate, sodium tripolyphosphate, tricalcium phosphate), “phosphoric acid,” or “pyrophosphate” (sodium acid pyrophosphate / SAPP) signals an inorganic additive source.

Note on Mediterranean diet compatibility: The mediterranean-diet pattern is structurally low in additive phosphate — its emphasis on whole grains, legumes, fish, fresh vegetables, EVOO, and minimally processed dairy naturally avoids the dominant additive categories. Patients already on a Mediterranean pattern will have low additive exposure; additive-reduction counselling is most impactful for Western-pattern eaters with high processed-food intake.

Biomarker monitoring option

Intact FGF23 (iFGF23): Available via Quest Diagnostics ( ~~$140-$ 165 self-pay) and LabCorp (~~ $150-$ 175 self-pay) as “Fibroblast Growth Factor 23 (FGF23), Intact.” Normal range in adults with preserved renal function is approximately 10–50 RU/mL (Immutopics ELISA assay; reference ranges vary by laboratory). iFGF23 responds measurably within days to weeks of dietary phosphate load change. Baseline measurement before dietary modification, repeat at 3–6 months, provides objective evidence of intervention response.

Serum phosphorus (standard CMP): Normal range 2.5–4.5 mg/dL in most adults. A value consistently at the high-normal end (>3.8–4.0 mg/dL) in a non-CKD adult warrants dietary additive review. Note: fasting serum phosphate is subject to circadian variation (nadir in AM, peak in PM) and carbohydrate intake influence; a single measurement has limited discriminatory value.

sKlotho (soluble Klotho): Available via research assays (IBL International ELISA, ~ $200-$ 350 self-pay if ordered); not on standard clinical panels. Normal adult range ~500–1,000 pg/mL with substantial inter-laboratory variation. Less practical as a monitoring tool than iFGF23 but theoretically the more direct readout of Klotho-axis status. no-mechanism — whether dietary additive reduction in non-CKD adults measurably restores sKlotho has not been demonstrated in a controlled study.

Limitations and gaps

#gap/needs-replication — The Dhingra 2007 Framingham Offspring cohort finding of ~1.55× CV risk at upper-normal serum phosphate has not been replicated in a large pre-specified analysis with dietary intake data; serum phosphate reflects total exposure (organic + inorganic + endogenous production) and is only a proxy for additive intake specifically.
#gap/needs-human-replication — VSMC transdifferentiation by extracellular phosphate is demonstrated robustly in vitro and in animal models; the causal chain from dietary additive phosphate → serum phosphate elevation → VSMC calcification in humans has not been directly demonstrated by controlled intervention study.
#gap/long-term-unknown — No multi-year dietary additive reduction trial exists in non-CKD adults. Whether sustained additive reduction measurably slows coronary artery calcification progression or pulse-wave velocity over 3–5 years is unknown.
#gap/dose-response-unclear — The threshold of additive intake above which FGF23 elevation becomes sustained (rather than transiently postprandial) is not established. Estimates that 320–470 mg/day from additives produces sustained dysregulation are drawn from observational and review-level data.
#gap/no-mechanism — Direct evidence that additive phosphate reduction (vs. total phosphorus restriction) measurably lowers iFGF23 or sKlotho in healthy adults in a randomized controlled design is absent.
#gap/unsourced — Per-serving additive phosphate content figures in the source table above are drawn from review-level label-analysis data rather than direct wet-chemistry measurement of specific branded products; individual product content varies. Readers should check current ingredient labels on specific products.

Cross-references

fgf23 — the proximate biomarker protein; FGF23 elevation is the measurable consequence of inorganic phosphate load; sibling-seeded page
vascular-calcification — the downstream pathological process; the primary CV risk concern; sibling-seeded page
klotho — the obligate co-receptor for FGF23 signalling; Klotho decline links chronic FGF23 elevation to CV aging
fgf-signaling — pathway context for FGF23/FGFR1 co-receptor biology
mediterranean-diet — structural complement; a Med-diet whole-food pattern naturally eliminates dominant additive-phosphate categories without explicit restriction
chronic-inflammation — primary target hallmark; FGF23/phosphate axis dysregulation drives arterial wall inflammation
deregulated-nutrient-sensing — secondary target; phosphate is a sensed nutrient whose sensing axis (FGF23/Klotho/PTH/Vitamin D) is chronically dysregulated by high additive intake
senolytics — not directly linked; noted because vascular senescence (VSMC senescent phenotype post-calcification) is an independent downstream mechanism; phosphate reduction does not directly target senescent cell clearance

Footnotes

doi:10.3390/nu15163510 · Calvo MS, Dunford EK, Uribarri J · Nutrients 2023;15(16):3510 · PMID 37630701 · review · “Industrial Use of Phosphate Food Additives: A Mechanism Linking Ultra-Processed Food Intake to Cardiorenal Disease Risk?” · n=N/A (review + label analysis) · reviews additive-use categories (emulsifiers, moisture-retention, leavening, acidulant), bioavailability differential, FGF23 mechanism, regulatory gaps; NOVA food-classification framing · open-access gold · model: human (population-level dietary data review) · archive: pending download ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸
doi:10.3238/arztebl.2012.0049 · Ritz E, Hahn K, Ketteler M, Kuhlmann MK, Mann J · Deutsches Ärzteblatt International 2012;109(4):49–55 · PMID 22334826 · review (public-health) · “Phosphate additives in food — a health risk” · n=N/A (review) · argues for mandatory quantitative additive labeling; synthesizes bioavailability differential (~80–100% inorganic vs ~40–60% organic), additive intake estimates, FGF23 evidence, and regulatory context; cited 195 times (OpenAlex) · model: human (review) · archive: not_oa ↩ ↩² ↩³ ↩⁴
doi:10.1007/s00223-007-9011-7 · Karp HJ, Ekblad-Sekund GM, Kemi VE et al. · Calcified Tissue International 2007;81(4):245–254 · PMID 17401693 · controlled feeding study (crossover design) · “Acute effects of different phosphorus sources on calcium and bone metabolism in young women: a whole-foods approach” · n=16 (healthy women, ages 20–30, each participant completed 5 separate 24-hour sessions as her own control); documents source-specific differences in calcium/phosphate fluxes and PTH responses across phosphate sources (meat, cheese, whole grains, phosphate supplement); only the phosphate supplement significantly increased serum PTH; does not directly measure FGF23 · model: human (healthy young women) · archive: not_oa · cited 122 times (OpenAlex) ↩ ↩²
doi:10.1093/ndt/gfq316 · Gutiérrez OM, Isakova T, Smith K et al. · Nephrology Dialysis Transplantation 2010;25(12):3970–3978 · PMID 20530498 · controlled postprandial study · “Racial differences in postprandial mineral ion handling in health and in chronic kidney disease” · n=47 (28 healthy: 18 white + 10 Black; 19 CKD: 9 white + 10 Black); standardized meal (500 mg phosphorus); blood/urine sampled q30 min for 4 hours · KEY FINDING: postprandial FGF23 did NOT significantly change over 4 hours in either racial group or CKD status; serum phosphate did not significantly differ between groups over time; the main finding was ~30% lower fractional excretion of phosphate in Black vs white participants despite similar PTH and FGF23 levels, suggesting racial differences in renal sensitivity to phosphaturic hormones · model: human (healthy adults + CKD stages 2–4) · OA bronze · archive: downloaded · NOTE: this paper does NOT support the claim that FGF23 elevates within hours of inorganic phosphate ingestion; it was mischaracterized in an earlier version of this page ↩ ↩²
doi:10.1001/archinte.167.9.879 · Dhingra R, Sullivan LM, Fox CS et al. · Archives of Internal Medicine 2007;167(9):879–885 · PMID 17502528 · observational (prospective cohort) · “Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community” · n=3,368 (Framingham Offspring cohort) · CVD-free at baseline; median follow-up ~16 yr; serum phosphorus upper quartile vs lowest: ~1.55× higher incident CVD in multivariable-adjusted analysis; monotonic dose-response · model: human (US community cohort) · archive: not_oa · cited 850 times (OpenAlex) ↩
doi:10.1001/archinte.167.9.873 · Foley RN · Archives of Internal Medicine 2007;167(9):873 · review/editorial · “Phosphorus comes of age as a cardiovascular risk factor” · editorial contextualizing Dhingra 2007 within broader phosphate-CV literature; n=N/A · model: review · archive: not_oa ↩
doi:10.1016/j.ahj.2008.05.016 · Foley RN, Collins AJ, Ishani A, Kalra PA · American Heart Journal 2008;156(3):556–563 · PMID 18760141 · observational (prospective cohort) · “Calcium-phosphate levels and cardiovascular disease in community-dwelling adults: The Atherosclerosis Risk in Communities (ARIC) Study” · n=15,732 community-dwelling adults · follow-up 12.6 years · Ca × P product associated with stroke (HR 1.15, 95% CI 1.05–1.26, p=0.0017) and all-cause mortality (HR 1.15, 95% CI 1.09–1.20, p<0.0001); association with coronary heart disease was NOT significant (HR 1.03, 95% CI 0.98–1.08); serum phosphate alone showed similar patterns for stroke and mortality · model: human · archive: not_oa · cited 274 times (OpenAlex) ↩
doi:10.1111/nyas.12300 · Calvo MS, Tucker KL · Annals of the New York Academy of Sciences 2013;1301:1–9 · PMID data unavailable in this session · review · “Is phosphorus intake that exceeds dietary requirements a risk factor in bone health?” · covers cardiovascular, renal, and bone risk; estimates 320–470 mg/day additive phosphate in typical US processed-food diet; synthesizes FGF23 evidence base as of 2013 · model: human (review) · OA hybrid · archive: pending · cited 97 times (OpenAlex) ↩
doi:10.1093/ndt/gfq419 · Isakova T, Gutiérrez OM, Smith K et al. · Nephrology Dialysis Transplantation 2011;26(1):196–205 · PMID 20631407 · pilot RCT · “Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease” · n=39 CKD patients · dietary restriction + phosphate binders significantly reduced FGF23 in CKD; provides controlled evidence that dietary phosphate → FGF23 causal link is real; CKD context limits direct extrapolation to non-CKD adults · model: human (CKD stages 2–4) · archive: not_oa ↩

🧬 Aging Wiki

Explorer

phosphate-additive-reduction